Respiratory syncytial virus (RSV), which causes infection of the lungs and breathing passages, is a major cause of respiratory illness, especially in young children.
About Respiratory Syncytial Virus (RSV)
RSV - BACKGROUND
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections
among young children worldwide. RSV infections occur mostly in yearly epidemic outbreaks. It is highly contagious and spreads through droplets upon coughing or sneezing. Approximately 33.8 million episodes of RSVassociated acute lower respiratory infections occur in children worldwide every year. RSV infection causes a worldwide burden of morbidity and mortality and has been presented as the second main cause of death during infancy. It is estimated that 53.000 to 199.000 RSV-related deaths happen per year, of which 99% occur in developing countries. In Europe and the US, on average 1% of children in their 1st year of life are hospitalised with a severe infection. In Europe, RSV accounts for 42-45% of hospital admissions for lower respiratory tract infections in children under 2. In addition to being a severe acute disease, RSV infection has been linked to an increased risk of the development of asthma in later life.
RSV - EXISTING PROBLEMS
RSV is a complex public health problem. The level of clinical, industrial and public interest is only becoming proportionate to the magnitude of the problem. There are currently no vaccine
approaches and prophylaxis is limited to passive immunisation with palivizumab.
An unmet need exists for both (i) long-term development strategies for vaccine and immunoprophylaxis candidates against RSV and (ii) biosimilars that can replace off-patent palivizumab on the short-term. Although the recent increase in industrial activity in development of RSV therapeutics is apparent, concerted and timely solutions to the medical needs are not yet in sight. Key research questions can only be answered through multidisciplinary and networking approaches. ReSViNET is the first and the only international, integrated, multidisciplinary and translational research approach focused on RSV infections.
RSV is spread through direct contact. It can live on surfaces (such as counter tops or doorknobs) and on hands and clothing, so it can be easily spread when a person touches something contaminated.
RSV can spread rapidly through schools and childcare centers. Babies often get it when older siblings carry the virus home from school and pass it on to them. Almost all kids have been infected with RSV at least once by the time they are 2 years old.
RSV infections often occur in epidemics that last from late fall through early spring in Europe and the United States. In tropical areas of the world RSV epidemics often occur during the rainy season. Respiratory illness caused by RSV — such as bronchiolitis or pneumonia — usually lasts 1-2 weeks, but some cases may last several weeks.
Birth around the start of the RSV season is an important risk factor for severe course of disease in case of RSV infection.
By age 2, most children will have been infected with respiratory syncytial virus. Children who attend child care centers or who have siblings who attend day care are at a higher risk of exposure.
People at increased risk of severe — sometimes life-threatening — infections include:
But if a child requires hospital admissions or has severe co-morbidity, a doctor might want to make a specific diagnosis of viral etiology; in that case, RSV is identified in nasal secretions.
Polymerase Chain Reaction (PCR) on nasal aspirations is most sensitive. During infancy, PCR on mucus obtained by a swab also has high sensitivity. Direct immuno fluorescence only has sufficient sensitivity (>90%) in infants hospitalized for RSV infection.
There is no specific treatment for children with RSV infection. A monthly injection with palivizumab, a monoclonal against the RSV F glycoprotein, during the RSV season prevents RSV-related hopital admission in children with congenital heart disease and preterm children with gestational age <= 35 weeks.
Supportive care consists of:
ReSViNET scale APP for pediatric respiratory assessment is now available
DOWNLOAD HERE IOS - ANDROID
The application, developed by Hospital Clínico Universitario de Santiago, ResViNET and Gradiant, was officially presented at the International Congress of Respiratory Syncytial Virus recently held in Malaga, Spain. It is the only scale validated for infant acute respiratory distress in primary care whose objective is to facilitate communication between doctors and parents ReSViNET is the name of the scale created by the GENVIP Group (Genetics, Vaccines, Infections and Paediatrics Group) of the University Hospital of Santiago, REGALIP and the European network ReSViNET
Santiago, December 5, 2017.- The paediatricians of the Hospital Clínico Universitario de Santiago recently presented at the International Congress of Respiratory Syncytial Virus, held in Malaga, the mobile application ReSViNET Scale App, an application for iOS and Android devices that allows parents to assess acute respiratory distress in a way that can compare to that of a paediatrician. click here to read more.
RSV GOLD is an online accessible database containing information on individual RSV-related mortality cases. Health care providers and researchers from all over the world are encouraged to share cases of children dying from RSV infection.
These confidential and anonymous data will be used to understand clinical and socio-economic characteristics of children dying from RSV infection and to determine the worldwide age distribution of these children.
Click the link below to go to the RSV GOLD database website.
We are open to collaborate in any RSV related research activity varying from advice to the necessary multidisciplinary engagements and clinical networks eventually necessary to develop the project.
We are very interested to collaborate in designing and performing clinical trials on RSV therapeutics that are aimed at decreasing the RSV burden/decreasing disease severity and saving young lives especially in developing countries.
Please contact us for possibilities.